Research interests include clinical and translational research in new drug development, gastrointestinal and genito-urinary malignancies. Dr. Knox is also the Principal Investigator of trials in biliary, hepatocellular, esophageal and renal cell cancers.
Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations.
EMBO Mol Med. 2018 Sep 04;:
Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients.
J Gastrointest Cancer. 2018 Aug 16;:
Health-related quality of life measure distinguishes between low and high clinical T stages in esophageal cancer.
Ann Transl Med. 2018 Jul;6(13):270
Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):900-909
Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study.
Dis Esophagus. 2018 Jun 14;:
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Lancet Oncol. 2018 Jun 01;:
Cancer Discov. 2018 May 31;:
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.
Cancer Med. 2018 May 15;:
The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy.
Oncotarget. 2018 Apr 17;9(29):20439-20450
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Chair, Kidney Disease Oriented Group, National Cancer Institute of Canada
Chair, Hepatobiliary Disease Oriented Group, National Cancer Institute of Canada